ESS505 Pre-hysterectomy Protocol

Bayer

Status: Completed

Conditions: Contraception

Treatments: Device: ESS505 (Essure, BAY1454033); Device: ESS305 (Essure, BAY1454032); Device: ESS505-A (Essure, BAY1454033)

Study type: Interventional

Funder types: Industry

Identifiers

NCT01664052

ESS505-002 (Other Identifier)

17035

Details and patient eligibility

About

This study has been designed to evaluate an investigational model of the Essure System for Permanent Birth Control. The investigational device is designed to offer all the advantages of the currently approved device. In addition, the investigational device offers immediate, permanent contraception without a three-month waiting period or 90-day confirmation test. This study has been designed to evaluate the effectiveness of the investigational device in causing tubal occlusion from insert placement through three months of wearing.

Full description

This study has previously been posted by Conceptus, Inc. (US).

After acquiring Conceptus, Inc., Bayer HealthCare AG (Germany) is the sponsor of the trial.

Enrollment: 66 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects who are scheduled to undergo a Laparoscopically Assisted Vaginal Hysterectomy (LAVH), Total Abdominal Hysterectomy (TAH), Total Vaginal Hysterectomy (TVH), Total Laparoscopic Hysterectomy (TLH) with Bilateral Total Salpingectomy or Bilateral Salpingo-oophorectomy (BSO), or Laparoscopic Supracervical Hysterectomy (LSH)
• Subjects who are 18 years of age and older
• Subjects who are able and willing to provide written informed consent
• Subjects who agree to use a contraceptive method following Essure placement until the hysterectomy procedure

Exclusion criteria

• Subjects with bilateral proximal tubal occlusion
• Subjects who have undergone fallopian tube sterilization
• Subjects with known endometrial or myometrial pathology which is likely to prevent access to the fallopian tube ostia
• Subjects who are post-menopausal
• Subjects with pelvic inflammatory disease (PID)
• Subjects with gynecologic malignancy
• Pregnancy or suspected pregnancy
• Delivery or termination of a pregnancy less than 6 weeks before Essure micro-insert placement
• Known allergy to contrast media
• Any general health condition that may represent, in the opinion of the Investigator, an increased potential risk associated with participation

Trial design

66 participants in 2 patient groups

ESS505-A (Essure, BAY1454033)

Experimental group

Description:

Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert with minimal polyethylene terephthalate (PET) fibers (investigational device model ESS505-A) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement.

Treatment:

Device: ESS505-A (Essure, BAY1454033)

ESS 305/ESS 505 (Essure, BAY1454032/Essure, BAY1454033)

Experimental group

Description:

Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) and contralateral placement of the current commercially approved Essure device, model ESS305 followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.

Treatment:

Device: ESS505 (Essure, BAY1454033)

Device: ESS305 (Essure, BAY1454032)